R&D
2nd Peptide-Based Therapeutics Summit banner
Partner Content

2nd Peptide-Based Therapeutics Summit

With Merck’s oral PCSK9 inhibitor demonstrating strong phase 3 trial results, J&J’s IL23R antagonist peptide continuing its phase 3 journey, and Chugai advancing peptides into the intracellular

R&D
LEAP HR: Life Sciences West banner
Partner Content

LEAP HR: Life Sciences West

Join us in San Francisco, CA this April for LEAP HR: Life Sciences West to network with 200+ senior HR leaders